ライフサイエンスコーパス: continuous intravenous infusion

1 tumomab was administered in 28-day cycles by continuous intravenous infusion.

2 doses of 0.05 to 0.25 mg/kg/h for 10 days by continuous intravenous infusion.

3 s of cytarabine (100 mg per square meter) by continuous intravenous infusion.

4 eneficial actions, especially when used as a continuous intravenous infusion.

5 administered (3 to 7 mg/kg/d for 7 days) by continuous intravenous infusion.

6 dependent manner following a bolus dose and continuous intravenous infusion.

7 reated with a 12-day course of tacrolimus by continuous intravenous infusion.

8 All treated patients received dopamine as a continuous intravenous infusion.

9 fore transplant at a dose of 0.04 mg/kg/d by continuous intravenous infusion.

10 shion with no intravenous fluids (n = 24), a continuous intravenous infusion (0.3 mL/hr) of 0.9% sali

11 intravenous infusion for 3 hrs followed by a continuous intravenous infusion (1 mL/kg/hr) of 5% hyper

12 receive rigosertib 1800 mg per 24 h via 72-h continuous intravenous infusion administered every other

13 sine were investigated in 13 patients during continuous intravenous infusion and boluses of adenosine

14 unilateral treatment and 11.1% that of daily continuous intravenous infusions and oral valganciclovir

15 ng strategies have been initiated, including continuous intravenous infusions and subcutaneous IL-15

16 rse events, which is currently explored by a continuous intravenous infusion approach.

17 s with active HCL were treated with 2-CdA by continuous intravenous infusion at 0.1 mg/kg/d for a tot

18 A course of cladribine constituted a 7-day continuous intravenous infusion at a dose of 0.1 mg/kg/d

19 2-CdA was administered by continuous intravenous infusion at a dose of 0.1 mg/kg/d

20 8, 15, and 22 and heparin coadministered by continuous intravenous infusion at a dose of 0.13 mg/kg

21 h or without oblimersen 3 mg/kg/d as a 7-day continuous intravenous infusion (beginning 4 days before

22 Recombinant IL-2 9 x 10(6) IU/m2 daily by continuous intravenous infusion (c.i.v.) was given for 4

23 tereoisomer of leucovorin (LV) as a 132-hour continuous intravenous infusion (CIV) with cisplatin 100

24 senting levels I, II, and III) for 5 days by continuous intravenous infusion (CIV).

25 es were defined as paclitaxel 13.1 mg/m(2)/d continuous intravenous infusion (CIVI) for 4 days withou

26 nitially treated with paclitaxel 175 mg/m(2) continuous intravenous infusion (CIVI) over 3 hours.

27 ting doses of YM155 administered by 168-hour continuous intravenous infusion (CIVI).

28 d perhaps less toxic, when administered as a continuous intravenous infusion (CIVI).

29 tment consisted of topotecan 1.25 mg/m(2) by continuous intravenous infusion daily for 5 days and cyt

30 y 1 and fluorouracil 1,000 mg/m2/24 hours by continuous intravenous infusion day 1 through 4) or CP (

31 administering flavopiridol by a 24- to 72-h continuous intravenous infusion demonstrated no clinical

32 es free flavopiridol concentration and makes continuous intravenous infusion dosing ineffective.

33 platin (20 mg/m(2)/d), both given as 96-hour continuous intravenous infusions during weeks 1 and 4 of

34 Treatment with AEOL 10113 (continuous intravenous infusion) during 100% oxygen expo

35 romuscular-blocking agent be administered by continuous intravenous infusion early in the course of a

36 The schedule consisted of a 2-week continuous, intravenous infusion followed by a 2-week re

37 -15 at a dose of 20 mug/kg/d administered by continuous intravenous infusion for 10 days resulted in

38 Study medication was administered as a continuous intravenous infusion for 168 hrs.

39 GKI (intervention) or saline (control) as a continuous intravenous infusion for 24 h.

40 Tacrolimus monotherapy was administered via continuous intravenous infusion for 28 days then tapered

41 R75231 was given to the animals by continuous intravenous infusion for 30 min before ischem

42 and etoposide (60 mg/m(2) per day) (CDE) by continuous intravenous infusion for 4 days (96 hours) ev

43 Treatment included FU 200 mg/m2/d via continuous intravenous infusion for 4 weeks followed by

44 olus injection administered over 5-20 min or continuous intravenous infusion for 6-96 h on day 1 of e

45 eated with 2-CdA at a dose of 0.1 mg/kg/d by continuous intravenous infusion for 7 days.

46 at 0.087 or 0.1 mg/kg body weight per day by continuous intravenous infusion for 7 days.

47 nation with phenylbutyrate administered as a continuous intravenous infusion for varying dose and dur

48 n SAMe (150 mg/kg/day) was delivered through continuous intravenous infusion, hepatic SAMe levels rea

49 doses ranging from 3 to 7 mg/kg/d as a 5-day continuous intravenous infusion in cycle 1 and as a 7-da

50 travenous infusion in cycle 1 and as a 7-day continuous intravenous infusion in subsequent cycles eve

51 ian of 15 courses every 3 weeks as a 48-72 h continuous intravenous infusion (in 22 cases), with mesn

52 The observation that IL-15 administered by continuous intravenous infusion is able to induce marked

53 Terlipressin given by continuous intravenous infusion is better tolerated than

54 a 30-min intravenous bolus followed by a 4-h continuous intravenous infusion, is active in high-risk,

55 ous injection lorazepam (group A, n = 50) or continuous intravenous infusion midazolam (group B, n =

56 Unlike continuous intravenous infusions, neurotoxicity was not

57 Simultaneously, a continuous intravenous infusion of (1)(3)C-leucine and (

58 l artery occlusion and treated with either a continuous intravenous infusion of 0.9% saline or 3% hyp

59 /kg of midazolam over 15 mins, followed by a continuous intravenous infusion of 100 microg/kg/hr (n =

60 A continuous intravenous infusion of 5% glucose providing

61 lvic external beam radiotherapy (45 Gy) with continuous intravenous infusion of 5-fluorouracil and/or

62 tions comparable to those following low-dose continuous intravenous infusion of 5-FU.

63 ratios were determined in rats treated with continuous intravenous infusion of 7.5% hypertonic salin

64 MCE was performed by continuous intravenous infusion of a nitrogen-filled bil

65 rtery, FFRic), and 2 FFR measurements during continuous intravenous infusion of adenosine (140 mug/kg

66 ion, MBV and MFV were measured by CEU during continuous intravenous infusion of albumin microbubbles

67 The preoperative treatment plan consisted of continuous intravenous infusion of cisplatin and 5-FU an

68 Continuous intravenous infusion of EGFR-AS (2 mg/kg) dec

69 Three-day continuous intravenous infusion of either placebo or 1 o

70 e) by intravenous bolus, followed by a 72-hr continuous intravenous infusion of either rhIL-1ra (2.0

71 tients with acute heart failure to receive a continuous intravenous infusion of either ularitide at a

72 nter open trial comparing the effects of the continuous intravenous infusion of epoprostenol (formerl

73 Recently, continuous intravenous infusion of epoprostenol has been

74 As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced

75 tin (60 mg per square meter) on day 1, and a continuous intravenous infusion of fluorouracil (200 mg

76 ere randomized to receive either a low-dose, continuous intravenous infusion of iloprost (0.075 micro

77 After 60 mins, animals received either a continuous intravenous infusion of iloprost at 0.075 mic

78 and [15N]urea was determined after a primed continuous intravenous infusion of L-[15N]arginine (40 m

79 leucine metabolism postabsorptively using a continuous intravenous infusion of L-[C2H3, 1-(13)C]meth

80 instrumented Sprague-Dawley rats received a continuous intravenous infusion of LPS (15 microg kg(-1)

81 rumented male Sprague-Dawley rats received a continuous intravenous infusion of LPS (15 microg kg(-1)

82 bly masked, placebo-controlled trial using a continuous intravenous infusion of NAC (150 mg/kg/day in

83 dial NO synthase levels without the need for continuous intravenous infusion of NO donors and without

84 eated in a blinded randomized fashion with a continuous intravenous infusion of normal saline, 3% hyp

85 fail to improve on calcium channel blockers, continuous intravenous infusion of PGI2 improves surviva

86 Subjects received a continuous intravenous infusion of placebo or rTFPI at 0

87 Continuous intravenous infusion of prostacyclin is an ef

88 and women in the baseline state and during a continuous intravenous infusion of recombinant human ins

89 A 72-hr, continuous intravenous infusion of rhIL-1ra failed to de

90 Continuous intravenous infusion of rTAP (average dose, 1

91 Animals in the 28-day time point received continuous intravenous infusion of rTFPI or control solu

92 n images (Agilent 5500) were obtained during continuous intravenous infusion of the contrast agent De

93 ptor agonist desmopressin (1 nmol.kg(-1)) or continuous intravenous infusions of arginine vasopressin

94 monary hypertension of the newborn receiving continuous intravenous infusions of morphine sulfate and

95 Oral administration, but not continuous intravenous infusion, of sirolimus (SRL) in c

96 (HRS), terlipressin has been used either as continuous intravenous infusion or as intravenous boluse

97 it has a low oral availability and requires continuous intravenous infusion or multiple gram doses t

98 In animal models, heparin delivered as a continuous intravenous infusion or via frequent (BID) su

99 g/m(2) by intravenous bolus on day 1 or 72 h continuous intravenous infusion) or intensified doxorubi

100 on days 1 and 8 and ISIS-2503 6 mg/kg/d as a continuous intravenous infusion over 14 days of an every

101 roups of animals of each genotype received a continuous intravenous infusion over 30 min of phenyleth

102 e first 7 days and 28 mug/day thereafter) by continuous intravenous infusion over 4 weeks every 6 wee

103 AEG35156 was administered by continuous intravenous infusion over 7 days (7DI) or 3 d

104 ramine, and cimetidine and then treated with continuous intravenous infusion paclitaxel over 24 hours

105 nts were randomly assigned to receive either continuous intravenous infusion (TERLI-INF group) at the

106 Mean time to FFR was 100 +/- 27 s for continuous intravenous infusion versus 23 +/- 14 s for i

107 ompare the administration of terlipressin as continuous intravenous infusion versus intravenous bolus

108 h prior pelvic radiation) given as a 24-hour continuous intravenous infusion with courses repeated ev

109 h prior pelvic radiation) given as a 24-hour continuous intravenous infusion with courses repeated ev

110 a 30-min intravenous bolus followed by a 4-h continuous intravenous infusion would achieve serum conc